Anti-interlekuin-5 therapy for eosinophilic diseases;Anti-interleukin-5-therapie bei eosinophilen erkrankungen

Hautarzt

Volumn 58, Issue 2, 2007, Pages 122-127

  Simon, D ^a   Braathen, L R ^a   Simon, H U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anti IL 5 antibody; Atopic eczema; Eosinophils; Hypereosinophilic syndromes; Interleukin 5

Indexed keywords

INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; RESLIZUMAB; SCH 55700; SCH 557000; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; BLOOD ANALYSIS; BLOOD LEVEL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; EOSINOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DERMATITIS, ATOPIC; EOSINOPHILIA; EOSINOPHILS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; LEUKOCYTE COUNT;

EID: 33847210351     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1273-x     Document Type: Article

References (34)

1. Akdis CA, Akdis M, Simon D et al. (1999) T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 113: 628-634
2. Arora AS, Yamazaki K (2004) Eosinophilic esophagitis: asthma of the esophagus. Clin Gastroenterol Hepatol 2: 523-530
3. Buttner C, Lun A, Splettstoesser T et al. (2003) Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 21: 799-803
4. Cheng JF, Ott NL, Peterson EA et al. (1997) Dermal eosinophils undergo cytolytic degeneration. J Allergy Clin Immunol 99: 683-692
5. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27
6. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003) Eosinophil's role remains uncertain as anti-IL-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199-204
7. Garrett JK, Jameson SC, Thomson B et al. (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113: 115-119
8. Geveart P, Lang-Loidolt D, Lackner A et al. (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118: 1133-1141
9. Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105: 651-663
10. Gregory B, Kirchem A, Phipps S et al. (2003) Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor α-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor α expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor α expression. J Immunol 170: 5359-5366
11. Hamelman E, Gelfand EW (2001) IL-5-induced airway eosinophilia-the key to asthma? Immunol Rev 179: 182-191
12. Hart TK, Cook RM, Zia-Amirhosseini P et al. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 108: 250-257
13. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A (2001) Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 145: 720-729
14. Kips JC, O'Connor BJ, Langley SJ et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistant asthma: a pilot study. Am J Respir Crit Care Med 167: 1655-1659
15. Klion A, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113: 30-37
16. Leckie MJ, ten Brinke A, Khan J et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148
17. Leifermann KM, Ackermann SJ, Sampson HA et al. (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 313: 282-285
18. Mattes J, Yang M, Mahalingam S et al. (2002) Intrinsic defect in T cell production of interleukin (IL)-13 in the abscence of both IL-5 and eotaxin precludes the development of eosinophilia and airway hyperreactivity in experimental asthma. J Exp Med 195: 1433-1444
19. Menzies-Gow A, Flood-Page P, Sehmai R et al. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714-719
20. Mishra A, Rothenberg ME (2003) Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent manner. Gastroenterology 125: 1419-1427
21. Oldhoff JM, Darsow U, Werfel T et al. (2005) Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 60: 693-696
22. Phipps S, Flood-Page P, Menzies-Gow A et al. (2004) Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122: 1406-1412
23. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2332-2337.
24. Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59: 561-570
25. Simon D, Vassina E, Yousefi S et al. (2004) Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 114: 887-895
26. Simon D, Vassina E, Yousefi S et al. (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60: 944-951
27. Simon D, Marti H, Heer P et al. (2005) Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol 115: 1090-1092
28. Simon HU (1998) Eosinophil apoptosis in allergic diseases - an emerging new issue. Clin Exp Allergy 28: 1321-1324
29. Simon HU, Plötz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112-1120
30. Straumann A, Bauer M, Fischer B et al. (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108: 954-961
31. Straumann A, Spichtin HP, Grize L et al. (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125: 1660-1669
32. Straumann A, Simon HU (2004) The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 59: 15-25
33. Wang J, Palmer K, Lötvall J et al. (1998) Circulating, but not local lung, IL-5 is required for the development of antigen-induced airway eosinophilia. J Clin Invest 102: 1132-1141
34. Zhang J, Kuvelkar R, Murgolo NJ et al. (1999) Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 11: 1935-1944